Likelihood of Accepting Treatment of GLP-1 vs Existing MOUD Options Does offering semaglutide or tirzepatide as one of the options for AUD or OUD treatment increase the likelihood of patients accepting treatment vs only offering existing therapies like naltrexone, buprenorphine, or methadone
In liver diseases, improvement of clinical parameters
Liraglutide Can Reverse Memory Impairment, Synaptic Loss and Reduce Plaque Load in Aged APP/PS1 Mice, a Model of Alzheimers Disease
CMSs Medicare GLP-1 Bridge Program expands access to obesity treatments for Part D enrollees, raising key considerations for employers and retiree strategies
Research has confirmed that inhibiting polyamine biosynthesis with the ornithine decarboxylase inhibitor -difluoromethylornithine significantly mitigates increased BBB permeability, Evans blue extravasation, and brain tissue water content in models of cerebral ischemia (102)
GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials